---
layout: default
title: Voriconazole
description: "Voriconazole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 195
evidence_level: L5
indication_count: 0
---

# Voriconazole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>0</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Voriconazoleï¼šæŠ—é»´èŒè—¥ç‰©

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Voriconazole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Voriconazole æ˜¯ä¸€ç¨®å»£æ•ˆæŠ—é»´èŒè—¥ç‰©ï¼Œç”¨æ–¼æ²»ç™‚ä¾µçŠ¯æ€§éº´èŒç—‡åŠå…¶ä»–åš´é‡é»´èŒæ„ŸæŸ“ã€‚
TxGNN æ¨¡å‹**æœªé æ¸¬**å‡ºä»»ä½•æ–°çš„é©æ‡‰ç—‡ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ã€è¶³åˆ†æèŒ/é®åˆ€èŒæ„ŸæŸ“ã€é é˜²ä¾µå…¥æ€§é»´èŒæ„ŸæŸ“ |
| é æ¸¬æ–°é©æ‡‰ç—‡ |  |
| TxGNN é æ¸¬åˆ†æ•¸ | N/A |
| è­‰æ“šç­‰ç´š | N/A |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 35 å¼µ |
| å»ºè­°æ±ºç­– | ç„¡è€è—¥æ–°ç”¨å€™é¸ |

## ç‚ºä»€éº¼æ²’æœ‰é æ¸¬æ–°é©æ‡‰ç—‡ï¼Ÿ

Voriconazole æ˜¯ç¬¬äºŒä»£ä¸‰å”‘é¡æŠ—é»´èŒè—¥ç‰©ï¼Œé€éæŠ‘åˆ¶çœŸèŒç´°èƒè‰²ç´  P450 ä¾è³´æ€§ 14Î±-å»ç”²åŸºé…¶ï¼Œé˜»æ–·éº¥è§’å›ºé†‡åˆæˆï¼Œç ´å£çœŸèŒç´°èƒè†œå®Œæ•´æ€§ã€‚å…¶ä½œç”¨æ©Ÿè½‰é«˜åº¦å°ˆä¸€æ–¼çœŸèŒï¼Œå°äººé¡ç´°èƒå½±éŸ¿å°ã€‚ç”±æ–¼å…¶è—¥ç†ä½œç”¨é‡å°çœŸèŒç‰¹æœ‰çš„ä»£è¬é€”å¾‘ï¼ŒTxGNN çŸ¥è­˜åœ–è­œåˆ†ææœªç™¼ç¾èˆ‡å…¶ä»–éæ„ŸæŸ“æ€§ç–¾ç—…çš„é¡¯è‘—é—œè¯ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç„¡ç›¸é—œæ–°é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ã€‚

## æ–‡ç»è­‰æ“š

ç„¡ç›¸é—œæ–°é©æ‡‰ç—‡çš„æ–‡ç»è­‰æ“šã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ | ç‹€æ…‹ |
|---------|------|------|-----------|------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬023646è™Ÿ | é»´é£›è†œè¡£éŒ 200æ¯«å…‹ | è†œè¡£éŒ  | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ç­‰ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026309è™Ÿ | æ­ç™¬å¹³è†œè¡£éŒ 200æ¯«å…‹ | è†œè¡£éŒ  | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ç­‰ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026337è™Ÿ | å¨å‰‹é»´è†œè¡£éŒ 200æ¯«å…‹ | è†œè¡£éŒ  | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ç­‰ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027755è™Ÿ | æ­¢é»´æ·è†œè¡£éŒ 200æ¯«å…‹ | è†œè¡£éŒ  | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ç­‰ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬060356è™Ÿ | é é»´å‡æ™¶æ³¨å°„åŠ‘200æ¯«å…‹ | å‡æ™¶æ³¨å°„åŠ‘ | ä¾µçŠ¯æ€§éº´èŒç—‡ã€ä¾µçŠ¯æ€§å¿µç èŒæ„ŸæŸ“ç­‰ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥é™¸è¼¸å­—ç¬¬000853è™Ÿ | ä¼ç«‹åº·å”‘ï¼ˆåŸæ–™è—¥ï¼‰ | ç²‰åŠ‘ | æŠ—é»´èŒç”¨è—¥ | æœ‰æ•ˆ |

## å®‰å…¨æ€§è€ƒé‡

### é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆMajorï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| Triamcinolone | CYP3A4 æŠ‘åˆ¶ï¼Œå¢åŠ é¡å›ºé†‡æš´éœ² |
| Budesonide | CYP3A4 æŠ‘åˆ¶ï¼Œå¢åŠ é¡å›ºé†‡æš´éœ² |
| Loperamide | å¢åŠ  QT å»¶é•·é¢¨éšª |
| Chlorpropamide | å¢åŠ ä½è¡€ç³–é¢¨éšª |
| Glimepiride | å¢åŠ ä½è¡€ç³–é¢¨éšª |
| Dolasetron | å¢åŠ  QT å»¶é•·é¢¨éšª |
| Eliglustat | CYP3A4 æŠ‘åˆ¶ |
| Naloxegol | å¢åŠ é´‰ç‰‡é¡æˆ’æ–·ç—‡ç‹€é¢¨éšª |

### ä¸­åº¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆModerateï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| è³ªå­å¹«æµ¦æŠ‘åˆ¶åŠ‘ï¼ˆOmeprazole, Lansoprazole ç­‰ï¼‰ | CYP2C19 ç«¶çˆ­ |
| Dexamethasone | ç›¸äº’å½±éŸ¿ä»£è¬ |
| Clarithromycin | CYP3A4 æŠ‘åˆ¶ |
| Ondansetron, Palonosetron | æ½›åœ¨ QT å»¶é•· |
| Pioglitazone, Saxagliptin | å¢åŠ é™è¡€ç³–è—¥ç‰©æš´éœ² |
| Levofloxacin | QT å»¶é•·é¢¨éšª |

### é‡è¦å®‰å…¨è­¦èª

- **è¦–è¦ºéšœç¤™**ï¼šç´„ 30% æ‚£è€…å¯èƒ½å‡ºç¾å¯é€†æ€§è¦–è¦ºæ”¹è®Š
- **è‚æ¯’æ€§**ï¼šéœ€ç›£æ¸¬è‚åŠŸèƒ½
- **QT å»¶é•·**ï¼šé¿å…èˆ‡å…¶ä»–å»¶é•· QT è—¥ç‰©ä½µç”¨
- **å…‰æ•æ„Ÿæ€§**ï¼šé•·æœŸä½¿ç”¨å¢åŠ çš®è†šç™Œé¢¨éšª
- **CYP2C19 å¤šå‹æ€§**ï¼šåŸºå› å‹å½±éŸ¿è—¥ç‰©ä»£è¬

### æ²»ç™‚è—¥ç‰©ç›£æ¸¬

å»ºè­°é€²è¡Œ Voriconazole è¡€ä¸­æ¿ƒåº¦ç›£æ¸¬ï¼š
- ç›®æ¨™è°·æ¿ƒåº¦ï¼š1-5.5 mg/L
- æ¿ƒåº¦éä½ï¼šç™‚æ•ˆä¸è¶³
- æ¿ƒåº¦éé«˜ï¼šå¢åŠ æ¯’æ€§é¢¨éšª

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šFood reduces the oral absorption and bioavailability of voriconazole.  According to the product labeling, administration of multiple doses of voriconazole with high-fat meals decreased the mean peak p...
- å»ºè­°ï¼šTo ensure maximal oral absorption, voriconazole tablets and oral suspension should be taken at least one hour before or after a meal.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Long QT Syndrome** ğŸŸ¡ Moderate
- Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patient...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- The pharmacokinetics of voriconazole are not significantly altered by impaired renal function.  However, accumulation of the IV vehicle, sulfobutyl ether beta-cyclodextrin sodium (SBECD), occurs in patients with moderate or severe renal dysfunction (...

**Pancreatitis** ğŸŸ¡ Moderate
- Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation) should be monitored for the development of pancreatitis during voriconazole therapy.

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious u...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šç„¡è€è—¥æ–°ç”¨å€™é¸**

**ç†ç”±ï¼š**
Voriconazole çš„ä½œç”¨æ©Ÿè½‰é«˜åº¦å°ˆä¸€æ–¼çœŸèŒç´°èƒï¼ŒTxGNN æ¨¡å‹æœªç™¼ç¾å…·æœ‰è¶³å¤ è­‰æ“šæ”¯æŒçš„æ–°é©æ‡‰ç—‡å€™é¸ã€‚è©²è—¥ç‰©åœ¨ç¾æœ‰æŠ—é»´èŒé©æ‡‰ç—‡ä¸­å·²å±•ç¾å„ªç•°ç™‚æ•ˆã€‚

**è‡¨åºŠå»ºè­°ï¼š**
- ç¶­æŒç¾æœ‰æŠ—é»´èŒé©æ‡‰ç—‡çš„ä½¿ç”¨
- æ³¨æ„è—¥ç‰©äº¤äº’ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯ CYP3A4 å’Œ CYP2C19 ç›¸é—œè—¥ç‰©
- å»ºè­°é€²è¡Œæ²»ç™‚è—¥ç‰©ç›£æ¸¬ä»¥å„ªåŒ–ç™‚æ•ˆå’Œå®‰å…¨æ€§
- é•·æœŸä½¿ç”¨æ‚£è€…éœ€ç›£æ¸¬è¦–åŠ›å’Œçš®è†šè®ŠåŒ–


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Fenoprofen]({{ "/drugs/fenoprofen/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Carbenoxolone]({{ "/drugs/carbenoxolone/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Titanium Dioxide]({{ "/drugs/titanium_dioxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Voriconazoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/voriconazole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_voriconazole,
  title = {Voriconazoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/voriconazole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
